New osteoporosis drug is first to form bone

Article

The FDA recently approved teriparatide (rDNA origin) injection [Forteo, Eli Lilly], a recombinant form of human parathyroid hormone, for the treatment of postmenopausal women with osteoporosis who are at increased risk for fracture. Teriparatide is also indicated to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Related Content
© 2025 MJH Life Sciences

All rights reserved.